Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$55.90
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $183.5M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
17.4x
↓EV/EBITDA
8.6x
↓ROE
9.2%
↑Gross Margin
27.5%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
-31.9%
FCF margin
10.8%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $845.2M · net income $103.1M · FCF $91.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $845.2M | $845.2M | $902.6M | $816.8M |
| Net Income | $103.1M | $103.1M | $175.7M | $110.5M |
| EBITDA | $175.7M | $175.7M | $263.1M | $190.2M |
| EPS | — | — | 5.49 | 3.45 |
| Gross Margin | 27.5% | 27.5% | 32.2% | 27.5% |
| Operating Margin | 16.6% | 16.6% | 21.0% | 15.2% |
| Net Margin | 12.2% | 12.2% | 19.5% | 13.5% |
| Balance Sheet | ||||
| Debt/Equity | 0.12 | 0.12 | 0.17 | 0.24 |
| Cash Flow | ||||
| Free Cash Flow | $91.6M | $91.6M | $183.5M | $197.5M |
| Returns | ||||
| ROE | 9.2% | 9.2% | 16.4% | 11.5% |
| Valuation | ||||
| P/E | 17.41 | 17.41 | — | — |
| EV/EBITDA | 8.63 | 8.63 | — | — |
| P/B | 1.60 | 1.60 | — | — |
| Growth & Yield | ||||
| Revenue Growth | -6.4% | -6.4% | 10.5% | — |
| EPS Growth | — | — | 59.1% | — |
| Dividend Yield | 5.6% | 5.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.1%
Start / end P/E
n/dx → n/dx
EPS bridge
5.49 → n/d
Residual
-42.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.